Wasatch Biolabs offers novel native sequencing services to power the entire development process— from biomarker discovery to clinical validation—within our CLIA certified laboratory.

Leveraging NESSI-Seq, our proprietary Nanopore library preparation technology that enhances sensitivity, specificity, and data quality, we create custom gDNA and cfDNA assays tailored to your research and clinical needs.

Supported by a team of R&D scientists and laboratory compliance experts, we offer Fit-For-Purpose validations based on project requirements such as:

Clinical Laboratory Improvement Amendment (CLIA) Validation
Research Use Only (RUO) Development
Good Clinical Practice (GCP) Validation

Comprehensive Sequencing Solutions: From Whole-Genome Discovery to Targeted Precision

Native sequencing and methylation detection capture genomic features that reflect biological reality and can be directly utilized as powerful and informative biomarkers.

Our solutions range from low-pass whole genome sequencing for cell-free DNA (cfDNA), to targeted assays that provide higher coverage of difficult-to-sequence regions of the genome. We deliver accurate results on short tandem repeats (STRs), copy number variations (CNVs), base modifications like methylation and hydroxymethylation, and more—without PCR biases, bi-sulfite conversions, or batch effects.

Cell-free Whole Genome Methylation Sequencing

Explore genomic variants and methylation across the cell-free genome. With custom bioinformatic algorithms, this approach enables cfDNA quantification and cell-of-origin analyses for clinical and research applications.

Targeted gDNA & cfDNA Methylation Sequencing

Zoom in on regions of interest to develop custom sequencing panels with deeper genetic and epigenetic insights. Target up to 4,000 regions and achieve 400-2,400x enrichment with our proprietary hybridization protocol.

NESSI-Seq Select Advantages

This direct approach bypasses the need for bisulfite conversion and PCR amplification, eliminating their associated biases and DNA damage.
‍
Wasatch Biolabs’ native methylation sequencing technology leverages NESSI-Seq, a proprietary library preparation protocol, and third generation, Nanopore sequencing to directly detect native methylation and hydroxymethylation modifications.

Enables Analysis:

Structural Variants
Small Variants (SNPs)
Copy Number Variants
(CNVs, dependent on read length and depth)
Short Tandem Repeat Expansions (STRs, dependent on read length and depth)
Modified Bases (5mC, 5hmC; also 6mA for bacteria)
Phasing Data (dependent on read length and depth)

Optimized For:

Cell-free DNA (cfDNA)
Flash Frozen (FF) Tissue

WBL
Vs
Traditional
Approach

From research to clinical services, Wasatch BioLabs is your premier service provider for custom sequencing initiatives.

Our NESSI-Seq sequencing services simplify workflows and enhance data quality and output, providing unparalleled discovery and targeted solutions for your sequencing and epigenetic analyses.

"Discover how NESSI-Seq transforms cfDNA analysis, enabling precise cell-of-origin identification and quantification even at low concentrations."

Traditional short-read technologies and bisulfite methylation assays often lack the sensitivity, specificity, and capability to sequence challenging genes. The NESSI-Seq platform overcomes these limitations, equipping researchers and physicians with native-read sequencing tools for diverse research and clinical diagnostic applications.

Cell-of origin / species identification and quantification using methylation and genomic signals:

Cancer (Circulating Tumor Cells + DNA—CTCs + ctDNA)
Infectious Disease (Human & Environmental)
Non-Invasive Prenatal Testing
Cardiovascular Disease
Transplant Rejection

Download White Paper

Our Process

Wasatch Biolabs is more than just a service provider—we collaborate with you in assay development to ensure your project is set up for success from the very beginning.

Our process is dynamic and tailored to your project type and regulatory requirements:

Define Your Focus

Partner with the WBL team to explore your therapeutic area of interest, set clear objectives, and determine the best technology for your desired endpoints.

Target Specific Regions

Identify target genomic regions tailored to your project’s unique goals.

Design & Optimize

Develop and refine oligonucleotide probes for precise detection and robust analysis.

Validate the Assay

Conduct rigorous testing to ensure the assay meets all regulatory requirements and achieves its intended effectiveness.

SERVICES

Custom Assay Development

Clinical Laboratory Improvement Amendment (CLIA) Validation

Research Use Only (RUO) Development

Good Clinical Practice (GCP) Validation